An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonic therapy for osteoporosis. A.B. Hodsman, L.J. Fraher, T. Ostbye, J. Adachi, B. Steer. J. Clin. Invest. 91:1138-1148, 1993.
Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiescent cancellous surfaces. A.B. Hodsman, B.M. Steer. Bone. 14:523-527, 1993.
Long-term GnRHA with standard postmenopausal estrogen replacement failed to prevent vertebral bone loss in postmenopausal women. A.K. Sugimoto, A.B. Hodsman, J.A. Nisker. Fertility, Fertility & Sterility 60:672-674, 1993.
Regional variation of insulin-like growth factor-I (IGF-1) gene expression in mature rat bone and cartilage. D-A. Lazowski, L.J. Fraher, A.B. Hodsman, B.M. Steer, D. Modrowski, V.K.M. Han. Bone 15:563-576, 1994.
Comparison of the pharmacokinetics of parenteral parathyroid hormone (1-34) [PTH-)1-34)] and PTH-related peptide-(1-34) in healthy young humans. L.J. Fraher, K. Klein, R. Marier, D. Freeman, G.N. Hendy, D. Goltzman, A.B. Hodsman. J. Clin.Endocrinol.Metab. 80:60-64, 1995.
Reliability, validity and sensitivity to intervention of a questionnaire to evaluate disability in osteoporosis patients. E. Helmes, A. Hodsman, D. Lazowski, A. Bhardwaj, P. Nichol, D. Drost, L. Vanderburgh, L. Peterson. J. Gerentol: Medical Sciences, 50A: M91-M98, 1998.
Parathyroid hormone restores bone mass and enhances insulin-like growth factor-I gene expression in ovariectomized rats. P.H. Watson, D.A. Lazowski, V.K.M. Han, L.J. Fraher, B.M. Steer, A.B. Hodsman. Bone 16:357-365, 1995.
Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J.H. Toogood, J.C. Baskerville, A.E. Markov, A.B. Hodsman, L.J. Fraher, B. Jennings, R.G. Haddad, D. Drost. J. Allergy Clin. Immunol. 96:157-166, 1995.
Clinical utility of bone mass measurements in adults: Consensus of an international panel. P.D. Miller, S.L. Bonnick, C.Rosen, R.D. Alman, L.V. Avioli, J. Dequeker, D. Felsenberg, H.K. Genant, C. Gennari, K.D. Harper, A.B. Hodsman, P.D. Miller, M. Kleerekoper, C.A. Mautalen, M.R. McClung, P.J. Meunier, D.A. Nelson, N.F.A. Peel, L.G. Raisz, R.R.Recker, W.H. Utian, R.D. Wasnich, N.B. Watts. Calcif. Tissue Int. 58:207-214, 1996.
Expression of growth factor ligand and receptor genes in rat cancellous bone trabeculae and marrow. P.H. Watson, A.J. Watson, A.B. Hodsman. J. Mol. Endocrinol. 17:45-54, 1996.
Use of bisphosphonates in the treatment of osteoporosis. A.B. Hodsman, J. Adachi, W. Olszynski. Report from the 1995 Consensus Conference of the Osteoporosis Society of Canada. CMAJ 155:945-948, 1996.
Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada. CMAJ 155:1113-1129, 1996.
A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in post-menopausal women with osteoporosis. A.B. Hodsman, L.J. Fraher, T. Ostbye, J.D. Adachi, D.H. Taves, D. Drost, J Clin Endocrinol Metab, 82:620-628, 1997.
Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. J.D. Adachi, W.G. Bensen, J. Brown, D. Hanley, A. Hodsman, R. Josse, D.L. Kendler, B. Lentle, W. Olszynski, L-G. Ste.Marie, A. Tenenhouse, A.A. chines, New Engl J Med, 337:382-387, 1997. (Editorial, I.R. Reid, New Engl J Med, 337:420-421, 1997.)
Comparison of the response of pelvic and proximal tibial cancellous bone in rat to ovariectomy with estrogen replacement. A.B. Hodsman, M. Kiesel, L.J. Fraher, P.H. Watson and L.W. Stitt. Bone 23:267-274, 1998.
Bone mineral density
T scores: assessing the risk. Editorial, Clinical and Investigative Medicine,
21:94-96, 1998.